Page last updated: 2024-09-05

lapatinib and akt-i-1,2 compound

lapatinib has been researched along with akt-i-1,2 compound in 2 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (akt-i-1,2 compound)	Trials (akt-i-1,2 compound)	Recent Studies (post-2010) (akt-i-1,2 compound)
1,919	305	1,442	56	0	34

Protein Interaction Comparison

Protein	Taxonomy	akt-i-1,2 compound (IC50)
Low molecular weight phosphotyrosine protein phosphatase	Homo sapiens (human)	7.43
RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)	0.2748
RAC-beta serine/threonine-protein kinase	Homo sapiens (human)	0.5861
RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)	1.4843

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Morphy, R	1
Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V	1

Reviews

1 review(s) available for lapatinib and akt-i-1,2 compound

Article	Year
Selectively nonselective kinase inhibition: striking the right balance. Journal of medicinal chemistry, 2010, Feb-25, Volume: 53, Issue:4 Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Humans; Protein Binding; Protein Kinase Inhibitors; Structure-Activity Relationship	2010

Other Studies

1 other study(ies) available for lapatinib and akt-i-1,2 compound

Article	Year
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell, 2011, Jan-18, Volume: 19, Issue:1 Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays	2011

Article

Year

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Cancer cell, 2011, Jan-18, Volume: 19, Issue:1

Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays

2011